Login to Your Account

Clinic Roundup

Tuesday, March 22, 2011
United Therapeutics Corp., of Silver Spring, Md., completed enrollment in the FREEDOM-C(2) registration trial of its sustained-release oral formulation of treprostinil diethanolamine (UT-15C). The 16-week, international, double-blind, randomized, placebo-controlled trial enrolled 313 subjects with pulmonary arterial hypertension.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription